Unknown PHASE2 INTERVENTIONAL 2-arm NCT02022852

Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer

Efficacy and Safety of Neoadjuvant Chemo-chemoradio-chemo Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer: a Phase II Trial

Sponsor: Harbin Medical University

Conditions Rectal Cancer

Interventions Capecitabine XELOX

Updated 6 times since 2017 Last updated: Dec 23, 2013 Started: Jul 31, 2013 Primary completion: Jul 31, 2015 Completion: Jan 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Rectal Cancer and is currently ongoing. Harbin Medical University leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE2

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harbin Medical University

Data source: Harbin Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harbin, China